Do heterozygous HTRA1 mutations carriers form a distinct clinical entity?
CNS Neurosci Ther
.
2018 Dec;24(12):1299-1300.
doi: 10.1111/cns.13047.
Epub 2018 Aug 6.
Author
Anastasia Bougea
1
2
Affiliations
1
Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
2
1st Department of Neurology, National and Kapodistrian University of Athens, Medical School of Athens, Athens, Greece.
PMID:
30084173
PMCID:
PMC6490067
DOI:
10.1111/cns.13047
No abstract available
Publication types
Letter
Comment
MeSH terms
Cerebral Small Vessel Diseases*
Heterozygote
High-Temperature Requirement A Serine Peptidase 1
Humans
Mutation
Substances
High-Temperature Requirement A Serine Peptidase 1
HtrA1 protein, human